This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.

What’s new

ELIQUIS® (apixaban): Simple dosing for stroke prevention in NVAF, with or without food

Missed dose: If a dose is missed, take ELIQUIS immediately and then continue with twice-daily intake as before1

ELIQUIS can be taken with or without food1

In the ARISTOTLE clinical trial, the majority of patients in the ELIQUIS group were on ELIQUIS 5 mg BD (95.3%, n=8,692 / 9,120).2*

Liver function testing should be performed prior to initiating ELIQUIS.1

FOOTNOTES

* In the ARISTOTLE trial, a total of 18,201 patients with NVAF and one risk factor for stroke and mean CHADS2 score of 2.1 were randomised to ELIQUIS 5 mg BD (or 2.5 mg BD in selected patients [4.7%]) or warfarin adjusted to target INR range 2.0–3.0.2 Stroke or systemic embolism was the primary efficacy endpoint of the ARISTOTLE trial (haemorrhagic stroke, and ischaemic or undetermined stroke, were components of stroke) and major bleeding defined per ISTH criteria was the primary safety endpoint.2 Efficacy analyses were based on the intention-to-treat population. Safety analyses were based on patients who had at least one dose of study drug.2

BD = Twice Daily   CHADS2 = Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled)   CrCl = Creatinine Clearance   
INR = International Normalised Ratio   ISTH = International Society on Thrombosis and Haemostasis   NVAF = Non-Valvular Atrial Fibrillation

REFERENCES

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.org.uk.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.